Remepy Raises $36M Series A

Remepy, based in Ramat Gan, Israel, is a digital health company that integrates pharmaceutical treatments with personalized AI-driven therapeutic software. The company has successfully closed a $36 million Series A funding round, bringing its total capital raised to date to $62 million.

Investors

The funding round was led by OG Venture Partners and M Ventures, the corporate strategic venture arm of Merck KGaA. Additional participating investors included NFX, Qumra Capital, Tadmor Group, TechAviv, Vine Ventures, 97212 Ventures, Fresh Fund, PsyMed Ventures, and IT-Farm Corp.

Remepy Use of Funds

Remepy plans to utilize the capital to advance its lead Parkinson's disease candidate, Hybridopa, into a global Phase III clinical trial scheduled to begin in the fourth quarter of 2026. Furthermore, the funding will support the expansion of the company's hybrid drug pipeline and facilitate ongoing pharmaceutical co-development partnerships, including its strategic collaboration with Merck KGaA regarding the development of treatments for rare tumors.

About Remepy

Founded in 2022 by Michal Tsur, Or Shoval, Eran Etam, and Professor Amir Amedi, Remepy is based in Ramat Gan, Israel. The company focuses on the development of hybrid drugs that combine traditional pharmacological treatment with adaptive physical, cognitive, and behavioral interventions delivered through a proprietary software platform, aiming to improve patient outcomes through personalized intelligence.

Funding Details

Company Website: https://remepy.com

Company: Remepy
Raised: $36M
Round: Series A
Funding Date: August 13, 2026
Lead Investor: OG Venture Partners, M Ventures
Additional Investors: NFX, Qumra Capital, Tadmor Group, TechAviv, Vine Ventures, 97212 Ventures, Fresh Fund, PsyMed Ventures, IT-Farm Corp.
Software Category: Digital Health
Source: https://finance.biggo.com/news/01645655-ad39-4d54-8bda-66f0fb09c134